Nov 07, 2019 7:35am EST Data From Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients With Advanced Solid Tumors
Oct 31, 2019 7:35am EDT Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®
Oct 22, 2019 7:35am EDT Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference
Jul 17, 2019 8:27am EDT Intensity Therapeutics' INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology
Jun 01, 2019 7:35am EDT Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019
May 16, 2019 7:35am EDT Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019
May 14, 2019 7:35am EDT Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium
Apr 17, 2019 7:35am EDT Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
Feb 05, 2019 7:35am EST Intensity Therapeutics to Participate in Panel at 2019 BIO CEO & Investor Conference
